Highest-materiality recent filing
Cosmos Health authorizes up to $5M share repurchase program, representing ~50% of market cap
Board authorized repurchase of up to $5M of common stock over 6 months ending Dec 31, 2026.
Cosmos Health Q1 revenue +31% to $17.93M; net loss widens to $2.81M
Q1 revenue $17.93M, up 31% YoY from $13.71M; adjusted revenue $18.40M (+34.2%).
Revenue $65.3M (+20% YoY); gross profit $7.9M (+83%); gross margin 12.1% (+418 bps).
Cosmos Health receives Nasdaq bid-price deficiency notice; 180-day cure period
Received non-compliance letter on Dec 11, 2025 for bid price below $1.00 for 30 consecutive business days.
Cosmos Health Q3 2025 revenue $17.1M (+38% YoY), record gross margin 15.2%, cash jumps to $4.63M
Q3 2025 revenue $17.11M (up 38% YoY); gross profit $2.60M (+116%), gross margin 15.21% (vs 9.72%).
Cosmos Health regains compliance with Nasdaq minimum bid price requirement
Received Nasdaq notice on Oct 15, 2025 confirming compliance with Minimum Bid Price Rule.
Elected six directors: Siokas, Demetriades, Hoidas, Aslidis, Bhutawala, Karkantzos with majority votes.
Cosmos Health CEO letter details $300M digital asset facility, H1 revenue up 11.7%, 2027 guidance
Secured $300M senior secured convertible note; 72.5% net proceeds to digital treasury (ETH, BTC, SOL).
Cosmos Health closes $8M senior secured convertible note with 9% OID, conversion at $1.05
Issued $8M original principal 9% senior secured convertible note to institutional investor on August 7, 2025.
Cosmos Health secures up to $300M convertible note facility for Ethereum treasury strategy
Up to $300M in 9% senior secured convertible notes; initial $8M close on Aug 6, 2025.
Cosmos Health enters exclusive license for two cancer-treatment patents; up to EUR 7.5M buy-out
Exclusive worldwide license for two patents (filed 2016, 2017) to treat cancer; commercialize via R&D and trials.
Cosmos Health receives Nasdaq bid price deficiency notice; 180-day cure period
Nasdaq notified Cosmos Health of non-compliance with minimum $1.00 bid price rule as of Nov 6, 2024.
Cosmos Health enters warrant exchange agreement, issues 9.7M new warrants at $0.95
Holder exercised 4,874,126 December 2023 warrants at reduced price of $0.8701 per share.
Cosmos Health receives additional Nasdaq delinquency notice for late 10-K and 10-Q filings
Received Nasdaq delinquency letter on May 21, 2024 for failure to timely file Q1 2024 Form 10-Q and remaining delinquent on 2023 Form 10-K.
Cosmos Health dismisses KPMG amid dispute over inventory transactions; appoints RBSM
KPMG dismissed on April 26, 2024 after failing to complete 2023 audit timely; cites unresolved inventory concerns.
Cosmos Health dismisses KPMG, hires RBSM; KPMG flags possible illegal act, company disagrees
Dismissed KPMG as auditor immediately on April 26, 2024; KPMG unable to complete 2023 audit on time.
Cosmos Health dismisses KPMG as auditor; KPMG unable to complete FY2023 audit on time
Dismissed KPMG effective April 26, 2024; Audit Committee unanimous vote.
Cosmos Health receives Nasdaq late-filing notice for 2023 10-K; 60 days to submit compliance plan
Notice received April 17, 2024 for failure to file annual Form 10-K for FY 2023 by due date.
Cosmos Health receives Nasdaq bid-price deficiency notice; 180 days to cure
Nasdaq notified company on March 20, 2024 that bid price closed below $1.00 for 30 consecutive days.
Cosmos Health acquires 10 generic drug portfolio for $3.5M from related party
Acquired licenses/rights to 10 generic drugs from related party for €3.2M ($3.5M).
Cosmos Health enters warrant exchange at $1.45 strike; provides 2024 growth outlook
Warrant exchange with one holder: new warrants for up to 4,874,126 shares at $1.45 (200% of existing warrants; prior strike $2.75).
Cosmos Health projects $12.5M+ revenue from 2023 acquisitions; exchanges warrants at $1.45
Entered warrant exchange for 4,874,126 new shares at $1.45 (down from $2.75); AGP gets $215K fee.
Cosmos Health Q3 2023: Revenue $12.8M (+7% YoY), net loss $3.35M, Adj. EBITDA -$1.1M
Revenue $12.8M (+7% YoY); gross margin declined to 9.5% from 14.9% due to logistics mix.
Cosmos Health reports H1 2023 adjusted net income $3.01M, issues 2026 guidance of $180M revenue
H1 2023 Adjusted EBITDA of $3.01M (up 182% YoY) and Adjusted Net Income of $3.01M (up from -$0.09M loss).
Cosmos Health H1 2023 adjusted net income jumps 3550% to $3.01M, revenue down 6%
Q2 2023 revenue $12.36M (-6.4% YoY); H1 revenue $24.71M (-6.0% YoY) on currency headwinds.
Cosmos Health auditor Armanino resigns; KPMG hired; prior internal control weaknesses disclosed
Armanino LLP resigned effective upon engagement of new auditor or filing of Q3 10-Q, citing its transition away from public company audits.
Issued 2,116,936 common shares, 715,323 pre-funded warrants, and 1,935,484 common warrants in a $5.25M offering.
Cosmos Health completes Cana buy for $1.67M; assets valued over $10M, expects gain
Purchase price $1.67M (€800k cash + $800k stock at $17.25/share) for 100% of Cana; closed June 30, 2023.
Cosmos Health FY2022 revenue down 10.5% to $50.3M; positive adjusted EBITDA, debt reduced 76%
Revenue $50.3M vs $56.2M; constant-currency increase of $0.4M; net loss $13.8M vs $7.96M.
Cosmos Health issues €4.1M secured note to Cana Holdings; acquisition planned by March 31, 2023
Cosmos Health issued a €4.1M secured promissory note to Cana Holdings, bearing interest at 5% + 1-month LIBOR, maturing in 5 years.
Cosmos Health extends LOI to acquire Cana Labs; renegotiates payment terms
Updated binding LOI to acquire Greek pharma company Cana Laboratories; effective until May 31, 2023.
Cosmos Health raises $32.5M in registered direct offering and private placement at $11.50/unit
Gross proceeds of ~$32.5M from sale of 2,828,320 shares and warrants at $11.50/unit.
Cosmos Holdings 1-for-25 reverse stock split, name to Cosmos Health
Reverse stock split 1-for-25 effective Dec 16, 2022; CUSIP changes to 221413-305.
On September 20, 2023, Pavlos Ignatiades, our Chief Communications Officer, resigned effective immediately.
On February 1, 2023, Cosmos Health Inc. (the 'Company') announced the appointment of Nikos Bardakis (54), who comes with over two decades of international branded pharmaceutical sector experience, as the Chief Operating Officer (COO).
Nikos Bardakis will succeed Pavlos Ignatiades, who will assume the position of Chief Communications Officer (CCO).
Effective April 28, 2022, Peter Goldstein resigned from the Board of Directors (the “Board”) of Cosmos Holdings Inc. (the “Company”) and from the Board’s audit committee.
On April 28, 2022, the Board appointed Dr. Anastasios Aslidis to the Board of Directors and as a member of the Board’s audit committee.
Max materiality 0.85 · Median 0.65 · Most common event other_material